Evaluation of ACE Inhibitors and Statins in Adolescent Type 1 Diabetics
Introduction
Researchers have investigated the safety and efficacy of angiotensin-converting enzyme (ACE) inhibitors and statins for managing high urinary albumin levels in adolescents diagnosed with type 1 diabetes. Abnormally elevated levels of urinary albumin, a protein typically found in blood but seldom in urine, are linked to a heightened risk of kidney dysfunction and cardiovascular diseases. This risk is particularly pronounced among adolescent type 1 diabetics due to the increased albumin excretion associated with puberty.
Study Background
While ACE inhibitors and statins have been utilized to treat high urinary albumin levels in adult type 1 diabetics, their effectiveness and safety in adolescents had not been thoroughly researched. A recent study published in the New England Journal of Medicine aimed to explore the impact of these medications on urinary albumin levels in this age group.
Study Design
The study included children aged 10 to 16 years who had been diagnosed with type 1 diabetes for a minimum of one year. Participants underwent testing for albumin and creatinine levels to establish a baseline for comparison. Those with albumin-to-creatinine ratios in the upper third of the screened group were enrolled in the study. Exclusion criteria included high cholesterol or blood fat levels, non-diabetes-related high blood pressure, pregnancy, specific eye or kidney disorders, and participation in other clinical trials.
Participants were randomized to receive either the ACE inhibitor quinapril, the statin atorvastatin, both medications, or placebos. The initial dosage was set at 5 mg/day, with an increase to 10 mg/day after two weeks. Follow-ups occurred after the first month and then every three months, with blood and urine samples collected biannually. Female participants who had begun menstruation underwent pregnancy tests every six months. The study duration ranged from two to four years.
Assessment of Efficacy and Safety
Efficacy was measured based on changes in the urinary albumin-to-creatinine ratio, blood pressure, glomerular filtration rate (GFR), urinary albumin levels, and blood measurements of fat, cholesterol, and C-reactive protein. Safety evaluations included monitoring blood urea and electrolyte levels, estimated GFR, liver function, and changes in height, weight, and body mass index.
Of the 4,407 adolescents screened, 443 were enrolled, with an average follow-up period of approximately 2.6 years; 154 participants completed the full four years, while 78 withdrew. Compliance with the treatment regimens was recorded at 75%.
Study Findings
Results indicated that statin use correlated with lower cholesterol, fat levels, and C-reactive protein. Among participants on ACE inhibitors or placebo, 25% required a dosage reduction to 5 mg/day, mainly due to low blood pressure. Four serious adverse events were linked to ACE inhibitor use: two patients experienced significant reductions in GFR, one had elevated blood pressure, and one showed increased alanine aminotransferase levels, suggesting liver damage.
Overall, the study concluded that both ACE inhibitors and statins did not significantly impact the albumin-to-creatinine ratio in adolescent type 1 diabetics. Given the relatively short study duration, further research might clarify any potential long-term benefits of these medications in this demographic. Future studies may also explore the safety and efficacy of additional ACE inhibitors and statins beyond quinapril and atorvastatin.
Reference
Marcovecchio, M.L. et al. (2017). ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med DOI: 10.1056/NEJMoa1703518.